Browsing Tag
Darolutamide
3 posts
Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China
Not intended for U.S. and UK Media Berlin, March 20, 2023 – The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Nubeqa is already approved in China for the treatment of patients
Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer
Not intended for U.S. and UK Media Berlin, March 1, 2023 – The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa™ (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Nubeqa is
Adding Darolutamide: New SOC for Metastatic Prostate Cancer
New data suggest that adding darolutamide (Nubeqa) onto androgen deprivation therapy (ADT) and docetaxel should become a new standard of care for men with metastatic hormone-sensitive prostate cancer (mHSPC), say investigators reporting results from the phase 3 ARASENS study. The three drug combination significantly reduced the risk of death by 32.5% (hazard ratio [HR], 0.68;…